Colorectal Cancer: Prevention and Management of Metastatic Disease

Table 3

Data suggesting benefit from proactive use of cytoreductive surgery (CRS) and hyperthermic perioperative chemotherapy (HIPEC) in selected primary colorectal cancer patients.

(a)

Proactive CRS and HIPEC with primary colorectal cancer
Authors	Institution	Year	Number of patients	Treatment	Survival statistic
Pestieau and Sugarbaker [24]	Washington, DC	2000	5	EPIC	𝑃<0.0001
Tentes et al. [25]	Didimotichon, Greece	2013	41	HIPEC	𝑃<0.03
Noura et al. [26]	Osaka and Sakai, Japan	2011	31	IP MMC	𝑃<0.005
Braam et al. [27]	Nieuwegein, The Netherlands	2013	20	HIPEC	NA
Sammartino et al. [28]	Rome, Italy	2013	25	HIPEC	𝑃<0.03

(b)

CRS and HIPEC as proactive second-look
Authors	Institution	Year	Number of patients	Treatment	Disease-free survival
Elias et al. [34]	Villejuif, France	2008	29	HIPEC	59% at 29 months
Sugarbaker et al.	Washington, DC	2013	20	HIPEC	85% at 2 years
Delhorme et al. [36]	Strasbourg, France	2013	14	HIPEC	38% at 2 years

HIPEC: hyperthermic perioperative chemotherapy; EPIC: early postoperative intraperitoneal chemotherapy; IP MMC: intraperitoneal mitomycin C; NA: not available.